OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity

MT Newswires Live03-17

OPKO Health (OPK) said Monday it will work with Entera Bio (ENTX) to push an oral dual agonist for obesity and related conditions into clinical testing.

The drug combines OPKO's extended-release GLP-1/glucagon analog with Entera's tablet formulation technology, with an FDA filing planned later this year, OPKO said.

Under the agreement, OPKO will cover 60% of development expenses and Entera 40%, with ownership split along the same lines, the companies said.

To help cover its share, Entera said it sold roughly 3.7 million shares to OPKO for $2.17 each. If Entera decides to drop out, it will still retain a 15% stake.

Entera's shares were up more than 10% in recent Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2520230575?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-17 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520230575","market":"us","top_or_hot":-1,"title":"OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity","media":"MT Newswires Live","content":"<html><body><p> OPKO Health (OPK) said Monday it will work with Entera Bio (ENTX) to push an oral dual agonist for obesity and related conditions into clinical testing.</p><p>The drug combines OPKO's extended-release GLP-1/glucagon analog with Entera's tablet formulation technology, with an FDA filing planned later this year, OPKO said.</p><p>Under the agreement, OPKO will cover 60% of development expenses and Entera 40%, with ownership split along the same lines, the companies said.</p><p>To help cover its share, Entera said it sold roughly 3.7 million shares to OPKO for $2.17 each. If Entera decides to drop out, it will still retain a 15% stake.</p><p>Entera's shares were up more than 10% in recent Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-17 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> OPKO Health (OPK) said Monday it will work with Entera Bio (ENTX) to push an oral dual agonist for obesity and related conditions into clinical testing.</p><p>The drug combines OPKO's extended-release GLP-1/glucagon analog with Entera's tablet formulation technology, with an FDA filing planned later this year, OPKO said.</p><p>Under the agreement, OPKO will cover 60% of development expenses and Entera 40%, with ownership split along the same lines, the companies said.</p><p>To help cover its share, Entera said it sold roughly 3.7 million shares to OPKO for $2.17 each. If Entera decides to drop out, it will still retain a 15% stake.</p><p>Entera's shares were up more than 10% in recent Monday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2520230575","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520230575","pubTimestamp":1742215036,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"OPKO Health  said Monday it will work with Entera Bio  to push an oral dual agonist for obesity and related conditions into clinical testing.The drug combines OPKO's extended-release GLP-1/glucagon analog with Entera's tablet formulation technology, with an FDA filing planned later this year, OPKO said.Under the agreement, OPKO will cover 60% of development expenses and Entera 40%, with ownership split along the same lines, the companies said.To help cover its share, Entera said it sold roughly 3.7 million shares to OPKO for $2.17 each. If Entera decides to drop out, it will still retain a 15% stake.Entera's shares were up more than 10% in recent Monday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","BK4144":"石油与天然气的储存和运输","BK4590":"PTP","OPK":"Opko Health","GLP":"全球合伙","ENTX":"Entera Bio Ltd.","BK4139":"生物科技"},"translate_title":"OPKO与Entera共同开发口服GLP-1/胰高血糖素治疗肥胖症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENTX":0.9,"GLP":1,"OPK":0.9},"content_text":"OPKO Health (OPK) said Monday it will work with Entera Bio (ENTX) to push an oral dual agonist for obesity and related conditions into clinical testing.The drug combines OPKO's extended-release GLP-1/glucagon analog with Entera's tablet formulation technology, with an FDA filing planned later this year, OPKO said.Under the agreement, OPKO will cover 60% of development expenses and Entera 40%, with ownership split along the same lines, the companies said.To help cover its share, Entera said it sold roughly 3.7 million shares to OPKO for $2.17 each. If Entera decides to drop out, it will still retain a 15% stake.Entera's shares were up more than 10% in recent Monday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2520230575"}